Denali Therapeutics Inc. Net Income
Denali Therapeutics Inc. (DNLI) reported Net Income of -$127.55 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-08-06
- Denali Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$127.55M.
- Denali Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$128.45M.
- Denali Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$128.55M.
- Denali Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$126.90M.
- Denali Therapeutics Inc. net income (loss) attributable to parent for fiscal 2020 was $71.14M.
- Denali Therapeutics Inc. net income (loss) attributable to parent for fiscal 2019 was -$197.61M.
- Denali Therapeutics Inc. net income (loss) attributable to parent for fiscal 2018 was -$36.24M.
- Denali Therapeutics Inc. net income (loss) attributable to parent for fiscal 2017 was -$88.19M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$127.55M 10-Q · filed 2026-08-06 | -$256.00M 10-Q · filed 2026-08-06 | -$384.55M derived: sum of 3 quarters · filed 2026-08-06 | -$511.45M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$128.45M 10-Q · filed 2026-05-07 | -$257.00M derived: sum of 2 quarters · filed 2026-05-07 | -$383.90M derived: sum of 3 quarters · filed 2026-05-07 | -$508.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$128.55M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-21 | -$255.45M derived: sum of 2 quarters · filed 2026-04-21 | -$379.57M derived: sum of 3 quarters · filed 2026-08-06 | -$512.54M DEF 14A · filed 2026-04-21 |
| 2025-09-30 | -$126.90M 10-Q · filed 2025-11-06 | -$251.02M derived: sum of 2 quarters · filed 2026-08-06 | -$383.99M 10-Q · filed 2025-11-06 | -$498.74M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$124.12M 10-Q · filed 2026-08-06 | -$257.09M 10-Q · filed 2026-08-06 | -$371.84M derived: sum of 3 quarters · filed 2026-08-06 | -$479.03M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$132.97M 10-Q · filed 2026-05-07 | -$247.72M derived: sum of 2 quarters · filed 2026-05-07 | -$354.92M derived: sum of 3 quarters · filed 2026-05-07 | -$453.94M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$114.75M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-21 | -$221.94M derived: sum of 2 quarters · filed 2026-04-21 | -$320.97M derived: sum of 3 quarters · filed 2026-04-21 | -$422.77M DEF 14A · filed 2026-04-21 |
| 2024-09-30 | -$107.19M 10-Q · filed 2025-11-06 | -$206.22M derived: sum of 2 quarters · filed 2025-11-06 | -$308.02M 10-Q · filed 2025-11-06 | -$427.49M derived: sum of 4 quarters · filed 2026-04-21 |
| 2024-06-30 | -$99.03M 10-Q · filed 2025-08-11 | -$200.83M 10-Q · filed 2025-08-11 | -$320.30M derived: sum of 3 quarters · filed 2026-04-21 | -$419.65M derived: sum of 4 quarters · filed 2026-04-21 |
| 2024-03-31 | -$101.80M 10-Q · filed 2025-05-06 | -$221.28M derived: sum of 2 quarters · filed 2026-04-21 | -$320.63M derived: sum of 3 quarters · filed 2026-04-21 | -$137.25M derived: sum of 4 quarters · filed 2026-04-21 |
| 2023-12-31 | -$119.47M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-21 | -$218.83M derived: sum of 2 quarters · filed 2026-04-21 | -$35.44M derived: sum of 3 quarters · filed 2026-04-21 | -$145.22M DEF 14A · filed 2026-04-21 |
| 2023-09-30 | -$99.35M 10-Q · filed 2024-11-06 | $84.03M derived: sum of 2 quarters · filed 2024-11-06 | -$25.75M 10-Q · filed 2024-11-06 | -$124.43M derived: sum of 4 quarters · filed 2026-04-21 |
| 2023-06-30 | $183.38M 10-Q · filed 2024-08-01 | $73.60M 10-Q · filed 2024-08-01 | -$25.08M derived: sum of 3 quarters · filed 2026-04-21 | -$128.38M derived: sum of 4 quarters · filed 2026-04-21 |
| 2023-03-31 | -$109.78M 10-Q · filed 2024-05-07 | -$208.46M derived: sum of 2 quarters · filed 2026-04-21 | -$311.76M derived: sum of 3 quarters · filed 2026-04-21 | -$370.55M derived: sum of 4 quarters · filed 2026-04-21 |
| 2022-12-31 | -$98.68M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-21 | -$201.98M derived: sum of 2 quarters · filed 2026-04-21 | -$260.77M derived: sum of 3 quarters · filed 2026-04-21 | -$325.99M DEF 14A · filed 2026-04-21 |
| 2022-09-30 | -$103.30M 10-Q · filed 2023-11-07 | -$162.09M derived: sum of 2 quarters · filed 2023-11-07 | -$227.31M 10-Q · filed 2023-11-07 | -$302.57M derived: sum of 4 quarters · filed 2026-04-21 |
| 2022-06-30 | -$58.79M 10-Q · filed 2023-08-08 | -$124.01M 10-Q · filed 2023-08-08 | -$199.28M derived: sum of 3 quarters · filed 2026-04-21 | -$283.86M derived: sum of 4 quarters · filed 2026-04-21 |
| 2022-03-31 | -$65.22M 10-Q · filed 2023-05-08 | -$140.48M derived: sum of 2 quarters · filed 2026-04-21 | -$225.07M derived: sum of 3 quarters · filed 2026-04-21 | -$285.76M derived: sum of 4 quarters · filed 2026-04-21 |
| 2021-12-31 | -$75.26M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-21 | -$159.85M derived: sum of 2 quarters · filed 2026-04-21 | -$220.54M derived: sum of 3 quarters · filed 2026-04-21 | -$290.58M DEF 14A · filed 2026-04-21 |
| 2021-09-30 | -$84.59M 10-Q · filed 2022-11-03 | -$145.28M derived: sum of 2 quarters · filed 2022-11-03 | -$215.32M 10-Q · filed 2022-11-03 | $29.57M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$60.69M 10-Q · filed 2022-08-08 | -$130.73M 10-Q · filed 2022-08-08 | $114.15M derived: sum of 3 quarters · filed 2023-02-27 | $55.92M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | -$70.04M 10-Q · filed 2022-05-05 | $174.84M derived: sum of 2 quarters · filed 2023-02-27 | $116.62M derived: sum of 3 quarters · filed 2023-02-27 | $57.86M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $244.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $186.66M derived: sum of 2 quarters · filed 2023-02-27 | $127.90M derived: sum of 3 quarters · filed 2023-02-27 | $71.14M 10-K · filed 2023-02-27 |
| 2020-09-30 | -$58.23M 10-Q · filed 2021-11-04 | -$116.99M derived: sum of 2 quarters · filed 2021-11-04 | -$173.75M 10-Q · filed 2021-11-04 | -$227.77M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | -$58.76M 10-Q · filed 2021-08-04 | -$115.52M 10-Q · filed 2021-08-04 | -$169.55M derived: sum of 3 quarters · filed 2021-08-04 | -$215.81M derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-03-31 | -$56.76M 10-Q · filed 2021-05-05 | -$110.79M derived: sum of 2 quarters · filed 2021-05-05 | -$157.05M derived: sum of 3 quarters · filed 2021-05-05 | -$215.38M derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | -$54.02M 10-K · filed 2020-02-27 | -$100.28M derived: sum of 2 quarters · filed 2020-11-05 | -$158.62M derived: sum of 3 quarters · filed 2020-11-05 | -$197.61M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$46.26M 10-Q · filed 2020-11-05 | -$104.60M derived: sum of 2 quarters · filed 2020-11-05 | -$143.59M 10-Q · filed 2020-11-05 | -$66.06M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | -$58.34M 10-Q · filed 2020-08-07 | -$97.33M 10-Q · filed 2020-08-07 | -$19.80M derived: sum of 3 quarters · filed 2020-08-07 | -$55.17M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | -$38.99M 10-Q · filed 2020-05-07 | $38.54M derived: sum of 2 quarters · filed 2020-05-07 | $3.17M derived: sum of 3 quarters · filed 2020-05-07 | -$51.55M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $77.53M 10-K · filed 2020-02-27 | $42.16M derived: sum of 2 quarters · filed 2020-02-27 | -$12.56M derived: sum of 3 quarters · filed 2020-02-27 | -$36.24M 10-K · filed 2021-02-26 |
| 2018-09-30 | -$35.37M 10-K · filed 2020-02-27 | -$90.09M derived: sum of 2 quarters · filed 2020-02-27 | -$113.77M 10-Q · filed 2019-11-06 | -$136.66M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | -$54.72M 10-K · filed 2020-02-27 | -$78.40M 10-Q · filed 2019-08-06 | -$101.29M derived: sum of 3 quarters · filed 2020-02-27 | -$123.13M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | -$23.68M 10-K · filed 2020-02-27 | -$46.56M derived: sum of 2 quarters · filed 2020-02-27 | -$68.41M derived: sum of 3 quarters · filed 2020-02-27 | -$90.54M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | -$22.89M 10-K · filed 2019-03-12 | -$44.73M derived: sum of 2 quarters · filed 2019-03-12 | -$66.86M derived: sum of 3 quarters · filed 2019-03-12 | -$88.19M 10-K · filed 2020-02-27 |
| 2017-09-30 | -$21.84M 10-K · filed 2019-03-12 | -$43.98M derived: sum of 2 quarters · filed 2019-03-12 | -$65.30M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | -$22.13M 10-K · filed 2019-03-12 | -$43.45M 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | -$21.32M 10-K · filed 2019-03-12 | |||
| 2016-12-31 | -$86.65M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |